CU 25. A preliminary clinical study of 2 - micron laser transurethral resection of ureteral cancer: Report of 8 cases

Objective: To evaluate the efficacy and safety of RevoLix 2 micron laser transurethral resection of ureteral tumor.

Methods: We retrospectively analyzed the clinical data of 8 patients (mean age: 70 years) underwent RevoLix 2 micron laser transurethral resection for ureteral tumors in our hospital from March 2010 to December 2010. Five patients had a history of cardiac stent implantation, and all patients had varied degrees of hypertension, diabetes, coronary heart disease, history of cerebral infarction or cerebral hemorrhage.

Results: The ureteral tumor length was about 1-3 cm. The mean operation duration was 16 min (8-35 min). All patients had no ureteral perforation and ureteral stripping, and no blood transfusion cases occurred. Conventional indwelling double-J tube was placed and it was pulled out four weeks after operation in the outpatient rooms. Postoperative pathological samples were obtained in four patients with non-muscle invasive ureteral cancer (low level), three patients with non-muscle invasive ureteral cancer (high level), and one patient with muscle invasive ureteral cancer (high level). All patients were followed for about 3 months to 6 months, and no tumor occurred.

Conclusions: For the patients with ureteral cancer who can not tolerate radical surgery, palliative transurethral resection of RevoLix 2 micron laser is effective, safe and reliable during shortterm follow-up.